Radiation Therapy-based Glioblastoma Multiforme Treatment Market Size (2025-2030)

The Radiation Therapy-based Glioblastoma Multiforme Treatment Market was valued at USD 3.72 billion in 2024 and is projected to reach a market size of USD 6.13 billion by the end of 2030. Over the forecast period of 2025-2030, the market is projected to grow at a CAGR of 8.68%.

The Radiation Therapy-based Glioblastoma Multiforme (GBM) Treatment Market represents a segment of cancer therapeutics that primarily employs cutting-edge radiation techniques to control and cure glioblastoma, an extremely aggressive and lethal brain cancer. The market has been on a steady rise as a consequence of the increasing incidences of GBM worldwide and the realizations made in the radiation-delivery technologies typical of IMRT (intensity-modulated radiation therapy), SRS (stereotactic radiosurgery), and proton therapy. Medical services providers are eager to employ these precision-centered therapies for the best tumor management while harming the healthy tissue around the tumor as minimally as possible, thus lengthening patients' survival and making their lives more comfortable. The market is also fueled by research efforts that are seeking to combine radiation therapy with immunotherapy and targeted agents, thus inventing novel multimodal treatment approaches. The regional dynamics factor significantly into this, with the technologically advanced regions like North America and Europe being the leaders in the adoption of the technology, while the developing markets in the Asia-Pacific region are experiencing a rapid increase in the health sector due to the rise in healthcare expenditure and the growing awareness of advanced cancer treatments among the public. Moreover, the partnerships between the pharmaceutical companies, hospitals, and research institutions are easing the pace of novel therapeutic solution enrollment, making the Radiation Therapy-based GBM Treatment Market a vital and rapidly changing sector of modern oncology.

Key Market Insights:

Infrastructure shortfalls: uneven machine distribution creates high-growth regional pockets.
There are 8,800 radiotherapy centers globally with >16,000 teletherapy machines and 3,000 brachytherapy resources, yet radiotherapy units per million population vary widely by country, signaling fast-growth potential in regions with current undersupply (notably parts of Asia, Africa, and Latin America). Product/service providers that combine financing, maintenance, and training can capture these underserved markets. International Atomic Energy Agency+1

AI and automation in radiotherapy planning are maturing dramatic efficiency gains translate to adoption incentives. Automated AI contouring and planning tools have shown the ability to reduce planning time from 150 minutes (manual) to under 5 minutes (AI), a step-change that can reduce bottlenecks, lower operational costs, and shorten waitlists, making AI-enabled software a high-value add-on for radiotherapy centers. Major tech-trend reports also highlight growing institutional interest in AI to improve throughput and consistency.

Market Drivers:

Rising Incidence of Glioblastoma Multiforme Accelerating Radiation Therapy Adoption.

Radiation-based solutions have remained the biggest demand driver in the fight against the rising global prevalence of Glioblastoma Multiforme (GBM), one of the most aggressive brain tumors, over the past several years. As the tumor is spread extensively in the brain, surgical removal is still very limited, so radiotherapy has become the main method of treatment for GBM. So, the worldwide rise in new cases, combined with the increased awareness of the importance of early diagnosis, has caused the demand for high-tech radiation therapy, such as intensity-modulated and proton beam therapies, to skyrocket. This increase in the number of patients is causing health care systems to invest more and more in the infrastructure of radiation therapy, thus resulting in constant market growth and increasing the number of technological innovations in both developed and emerging countries.

Advancements in Personalized Radiotherapy Driving Precision Treatment Approaches.

Rapid personalized radiotherapy innovations are progressively changing glioblastoma (GBM) treatment outcomes through the integration of advanced imaging, data analytics, and AI-driven modeling. Oncologists are now able to tailor dose distribution based on individual tumor behavior and anatomical changes with the help of cutting-edge methods such as image-guided radiation therapy (IGRT) and adaptive radiation therapy (ART). These techniques reduce the irradiation of healthy tissues while increasing the precision of the treatment and the survival rates. The use of AI-based treatment planning and multimodal imaging fusion is also leading to the acceleration of precision oncology trends in the management of GBM. As healthcare providers continue to put more emphasis on customized, patient-centric therapies, personalized radiotherapy has become the main factor that drives the system's efficiency, safety, and clinical success thus, it is fueling the long-term growth of the global radiation therapy-based GBM treatment market.
 

Market Restraints and Challenges:

The market for Glioblastoma Multiforme (GBM) treatment based on radiation therapy is encountering significant restraints and challenges that affect its growth potential. One of the major issues is the high cost of the treatment, which results from the requirement of advanced radiation equipment and sophisticated therapy protocols. This situation makes it difficult for areas of low- and middle-income to access the treatment as they are the ones who suffer from limited reimbursement coverage. Consequently, this economic limitation not only hampers the level at which patients can get the most advanced treatments but also slows down the diffusion of new technologies. Besides that, the complicated nature of the GBM radiation therapy also leads to some clinical challenges since it is necessary to focus very accurately to avoid injuring the healthy brain tissue around. On top of that, the management of a possible severe side effect, such as cognitive decline and other neurological complications, makes the whole treatment planning and patient compliance process even more difficult. In sum, these financial and clinical obstacles have been a major factor in radiation therapy for GBM not being embraced as widely as it could, thus limiting overall market growth.
 

Market Opportunities:

The market for Glioblastoma Multiforme (GBM) treatment using radiation therapy has major openings resulting from the improvements in the accuracy of radiation technologies and the trend towards personalized oncology care. The quick growth of state-of-the-art radiation techniques such as proton therapy, stereotactic radiosurgery (SRS), and intensity-modulated radiotherapy (IMRT/VMAT) in the developing countries is a great source of potential for the companies operating in this market to penetrate the less developed healthcare infrastructures and satisfy the increasing clinical demand. Besides this, the situation is very promising as far as the industry is concerned, due to the radiation therapy becoming more and more tightly integrated with immunotherapies, cell-based treatments, and adaptive image-guided systems, thus opening up new opportunities for creating hybrid treatment models and companion diagnostics. As the research keeps on uncovering the synergistic benefits of combination therapies in patient survival rates, stakeholders can have a portfolio strengthened through the innovation-led collaborations, and their presence can be extended to the global next-generation GBM care.
 

RADIATION THERAPY-BASED GLIOBLASTOMA MULTIFORME TREATMENT MARKET REPORT COVERAGE:

Radiation Therapy-based Glioblastoma Multiforme Treatment Market Segmentation:

Radiation Therapy-based Glioblastoma Multiforme Treatment Market Segmentation By Type:

• Radiation Therapy
• Chemotherapy
• Surgery
• Targeted Therapy
• Immunotherapy
   

Out of all the treatments for Glioblastoma Multiforme, Radiation Therapy is still the major one that is used to control the tumor progression and thus to improve the patient's survival. Thus, basically, the scope of radiation therapy has been extended further by the introduction of advanced methods like intensity-modulated radiotherapy (IMRT), stereotactic radiosurgery (SRS), and proton therapy, which precisely pinpoint the cancerous cells while taking care of the healthy cells. The growth of this segment is a consequence of the rapid uptake of first-class radiation devices, increased knowledge about the benefits of non-invasive treatments, and the continuous rise of healthcare investments in oncological infrastructure. Both patients and doctors choose radiation therapy as the best weapon to fight cancer due to its effectiveness and shorter post-treatment recovery period; hence, it is the biggest segment in the market.

Targeted Therapy is rapidly becoming the next biggest subsegment, with its growth mainly driven by the advancements in molecular profiling and the personalized medicine approach. In order to make the treatment more precise and to lessen the systemic side effects, targeted therapy is used to selectively attack tumor cells that have certain genetic or molecular markers. The worldwide uptake is being facilitated by the pace of new studies and the growing number of regulatory approvals for novel targeted agents. Such swift expansion is indicative of the healthcare industry turning to more patient-centered treatment strategies and targeted therapies being used more and more in combination with traditional radiation protocols.
 

Radiation Therapy-based Glioblastoma Multiforme Treatment Market Segmentation By Application

• Oncology Centers
• Hospitals
• Clinical Trials
• Personalized Medicine
• Palliative Care
   

By and large, hospitals are the main hubs that control the market of radiation therapy-based GBM treatment. They are the ones where the bulk of patient diagnosis, treatment planning, and follow-up care takes place. With advanced radiotherapy setups such as intensity-modulated radiotherapy (IMRT) and stereotactic radiosurgery (SRS), hospitals can offer a complete care cycle to the patients. Moreover, a concentration of highly skilled oncologists, radiologists, and multidisciplinary teams is there to ensure the accurate and timely execution of complicated treatment regimens. The segment’s expansion is attributed to the increased spending by hospitals on state-of-the-art radiotherapy technologies, the rise in patient numbers, and the growth of healthcare infrastructure worldwide.

One of the main reasons that genomics, molecular profiling, and precision oncology have been able to advance so quickly is that Personalized Medicine has been the fastest-growing application segment by far. Through personalized radiotherapy, it is possible to adjust the treatment regimens based on the biologic characteristics of the tumor of each patient and thereby increase the treatment efficacy and lower the occurrence of side effects. Moreover, the integration of AI-powered treatment planning systems is fuelling the uptake of the technology by making it possible to deliver the radiation dose in the most efficient way, which results in better treatment outcomes. The exponential growth of this segment is a clear indication of how the industry is changing from a focus on targeted, patient-specific therapies to a demand for treatments that not only prolong life but also maintain its quality.


 

Radiation Therapy-based Glioblastoma Multiforme Treatment Market Segmentation: Regional Analysis:

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa

The United States and Canada together form the major market for radiation therapy-based glioblastoma multiforme (GBM) treatment in North America, which is the primary reason for advanced healthcare infrastructure, a large number of cancer cases, and the rapid utilization of frontier radiation technologies such as proton therapy and stereotactic radiosurgery (SRS). The region’s top medical device manufacturers, the presence of cancer treatment centers with the latest technologies, and the huge government and private investments in oncology research are a few factors that have made the North American market the strongest. Besides that, a high level of awareness of personalized medicine and the presence of reimbursement regulations that are supportive in nature have become the main factors for the U.S and Canada to be at the forefront in the deployment of advanced radiation therapies.

Asia-Pacific remains the fastest-expanding local market globally. The region's growth is supported by the rise in cancer cases, the development of healthcare facilities, and the lifting of restraints for very advanced radiation therapies. China, India, and Japan have become the main channels for hefty capital injection into state-of-the-art oncology centers and the use of innovative treatment modalities. Their rapid urbanization, rising healthcare spending, and various government programs to improve the quality of cancer care in the country are the main factors propelling the market to grow further. Besides that, the region is also expected to maintain a high momentum of oncology demand with more and more doctors skilled in cancer treatment and increasing liaison activities with selected global technology providers.
 

COVID-19 Impact Analysis:

The COVID-19 pandemic caused a significant upheaval in the market for Radiation Therapy-based Glioblastoma Multiforme (GBM) treatment, leading to numerous operational challenges and strategic changes within healthcare systems. At the peak of the pandemic, a number of oncology centers were closed, with the absolute majority of them reporting delays and deferrals of patient treatments of glioblastoma multiforme due to lockdowns, lack of medical staff, and the redeployment of resources to COVID-19 care. This created a situation in which the timely delivery of precision radiation therapies such as Intensity-Modulated Radiation Therapy (IMRT) and Stereotactic Radiosurgery (SRS) was compromised, thus leading to changes in patient outcomes. Moreover, the pandemic has accelerated the use of telemedicine consultations, remote patient monitoring, and follow-up care, thus provoking healthcare providers to implement digital tools in traditional GBM treatment workflows. The crisis has also led to the decision to invest in automated and minimally invasive radiation technologies, which will lower the number of patients' hospital visits and the associated exposure risks, even though the industry has been jolted by the situation. Different regions have fared differently throughout the pandemic: North America and Europe experienced the initial slowdowns in treatment and have been able to adjust quickly with hybrid care models, whereas developing regions have experienced longer periods of service suspensions caused by inadequate healthcare infrastructures. In short, COVID-19 put a spotlight on the necessity of resilient and flexible treatment strategies, which compelled the radiation therapy sector to digitalize, remotely plan, and use patient-centered approaches, thus making the GBM treatment environment safer and more efficient.
 

Latest Market News:

• In March 2024, AstraZeneca announced the acquisition of Canadian biotech company Fusion Pharmaceuticals for $2.4 billion. Fusion specializes in radioconjugates, a next-generation cancer treatment that targets cancer cells with radioactive isotopes, minimizing damage to healthy cells. This acquisition aims to enhance AstraZeneca's capabilities in targeted radiotherapy, including treatments relevant to GBM.
   
• In June 2025, Gilead Sciences, in collaboration with the University of Pennsylvania, reported that its experimental CAR-T cell therapy demonstrated significant effectiveness against recurrent glioblastoma. The therapy, which involves engineering a patient's own white blood cells to target and kill cancer cells, resulted in tumor shrinkage in 62% of patients with measurable tumors among 18 total participants. This advancement highlights the potential of combining immunotherapy with radiation-based approaches in GBM treatment.
   

Latest Trends and Developments:

The Glioblastoma Multiforme (GBM) Radiation Therapy-based treatment market is experiencing a variety of changes that are mainly influenced by technological upgradation and changes in therapy. Radiation therapy still plays an essential role in the management of GBM, and modern techniques are making it more accurate and less damaging to healthy tissue. The development of new treatments, for example, FLASH radiotherapy, a method in which extremely high doses are delivered in very short bursts, and Tumor Treating Fields (TTFields), which use low-intensity electric fields to interfere with cancer cell division, are changing the way treatments are being used. Moreover, CAR-T cell therapies aimed at specific tumor markers are the ones that lead to the most significant development results in the case of recurrent GBM and thus have the potential of being able to provide better results when combined with the currently used treatment methods. The use of these state-of-the-art technologies combined with the increasing focus on the importance of the patient-specific treatment plans is leading to a more targeted and efficient way of GBM treatment which in turn results in the prolongation of survival and improvement of the quality of life of patients all over the world, the latter being two things that have always been quite difficult to achieve in this disease.
 

Key Players in the Market:

1. Merck & Co., Inc.
2. Amgen, Inc.
3. F. Hoffmann-La Roche Ltd.
4. Pfizer Inc.
5. Teva Pharmaceutical Industries Ltd.
6. Sun Pharmaceutical Industries Ltd.
7. Varian Medical Systems, Inc.
8. Elekta AB
9. Bayer AG
10. Arbor Pharmaceuticals, LLC